X

Drug Profile

LPCN 2203

Alternative Names: LPCN-2203

Latest Information Update: 25 Mar 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lipocine
Class Antiepileptic drugs
Mechanism of Action GABA modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Essential tremor

Most Recent Events

12 Mar 2024 Lipocine plans to submit a protocol for a proof-of-concept phase-II trial for Essential tremor in the first half of 2024
31 Dec 2023 Lipocine completes phase-I trial in Essential tremor (In volunteers) (PO) before December 2023
31 Dec 2023 Lipocine plans phase-II trial for Essential tremor (PO) in

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com